Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.43 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869441 | 0.89 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TAAR1SLC6A4SLC6A2 | |
| SCHEMBL14869451 | 0.86 | TAAR1 (0.50) | ALDH1A1HSD17B10TAAR1SLC6A4SLC6A2 | |
| SCHEMBL14869448 | 0.77 | ESR1 (0.48) | ALDH1A1HSD17B10TAAR1SLC6A4SLC6A2 | |
| SCHEMBL2451349 | 0.76 | LMNA (0.56) | ALDH1A1 | |
| SCHEMBL14869455 | 0.75 | KDR (0.49) | ALDH1A1HSD17B10LTB4R | |
| SCHEMBL16312618 | 0.75 | HRH2 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3HRH2 | |
| SCHEMBL11693746 | 0.75 | HRH2 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3HRH2 | |
| SCHEMBL14869027 | 0.75 | TAAR1 (0.43) | ALDH1A1HSD17B10TAAR1SLC6A4SLC6A2 | |
| SCHEMBL14869454 | 0.74 | EED (0.40) | ALDH1A1HSD17B10 | |
| SCHEMBL14869028 | 0.74 | LTB4R (0.50) | ALDH1A1HSD17B10TAAR1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
| US-9481642-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9480663-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ALDH1A1 1040/4885HSD17B10 290/4885TAAR1 3026/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ALDH1A1 1040/4885HSD17B10 290/4885TAAR1 3026/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885HSD17B10 269/4885TAAR1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.